Autoimmune pulmonary alveolar proteinosis (aPAP) Epidemiology

Key Highlights

• Autoimmune pulmonary alveolar proteinosis accounts for 90% of pulmonary alveolar proteinosis (PAP) cases.
• Autoimmune pulmonary alveolar proteinosis is often underdiagnosed and underestimated. The underdiagnoses of Autoimmune pulmonary alveolar proteinosis may be due to the lack of awareness among physicians and the absence of specific diagnostic criteria in European countries.
• The diagnosis rate in Japan is high due to mandatory health screening, which helps identify asymptomatic patients. Not just that, Japan has a centralized network, and communication among different Autoimmune pulmonary alveolar proteinosis treatment centers and organizations is better in comparison to Western nations. Additionally, there is broad access to GM-CSF antibody testing in Japan.
• Savara plans to launch a website in 2023 for the US HCPs to increase HCPs awareness of aPAP, including hallmark symptoms of the disease, and to educate HCPs on the need for routine antibody testing. Savara seeks to change clinical diagnostic guidelines to accelerate testing.
• In 2022, the US accounted for the maximum patient share in the 7MM, i.e., 48%, followed by EU4 and the UK.
• Autoimmune pulmonary alveolar proteinosis was rare in the <18 age group.

DelveInsight’s “Autoimmune Pulmonary Alveolar Proteinosis (aPAP) – Epidemiology – 2034” report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology of Autoimmune pulmonary alveolar proteinosis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Autoimmune Pulmonary Alveolar Proteinosis Disease Understanding

Autoimmune Pulmonary Alveolar Proteinosis Overview

Autoimmune pulmonary alveolar proteinosis is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP). It is a disease characterized by alveolar filling that leads to progressive accumulation of surfactant in alveoli, hypoxemia, and the development of serious infections or pulmonary fibrosis in some patients. Autoimmune Pulmonary Alveolar Proteinosis represents about 90% of all patients with PAP. While Autoimmune pulmonary alveolar proteinosis can affect people of any age, race, or sex, onset occurs most frequently in people between 30 and 40.

Autoimmune Pulmonary Alveolar Proteinosis Diagnosis

The diagnosis of autoimmune PAP is challenged by its low prevalence, nonspecific symptoms, radiographic findings, minimal physical examination findings, and normal routine laboratory test results. It is usually misdiagnosed as pneumonia until the failure of several courses of “appropriate” therapy (antibiotics) prompts diagnostic reconsideration, referral, and disease-specific testing. Results from the US National PAP Registry indicate that an accurate diagnosis of PAP is delayed by a median of 1.5 years (interquartile range, 0.5–13.5 years) after the onset of symptoms. Thus, heightened awareness is important for a timely and accurate diagnosis.

Further details related to diagnosis are provided in the report…

Autoimmune Pulmonary Alveolar Proteinosis Epidemiology

As the market is derived using a patient-based model, the Autoimmune pulmonary alveolar proteinosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Autoimmune pulmonary alveolar proteinosis, gender-specific cases of Autoimmune pulmonary alveolar proteinosis, age-specific cases of Autoimmune pulmonary alveolar proteinosis, stage-specific cases of Autoimmune pulmonary alveolar proteinosis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034. The total diagnosed prevalent cases in the 7MM comprised approximately 7,860 cases in 2022 and are projected to increase during the forecast period.

• In the 7MM, the most diagnosed prevalent Autoimmune pulmonary alveolar proteinosis cases were seen in Japan, accounting for approximately 3,000 cases in 2022.
• Among EU4, Germany accounted for the highest number of Autoimmune pulmonary alveolar proteinosis cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• In age-specific cases of Autoimmune pulmonary alveolar proteinosis in 2022, the maximum number of cases were observed in the age group of 41–65.
• Males are more likely to get Autoimmune pulmonary alveolar proteinosis than females. In the United States in 2022, around 1,900 male Autoimmune pulmonary alveolar proteinosis cases were found.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Autoimmune pulmonary alveolar proteinosis evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, drug uptake, along with challenges related to accessibility, including Pulmonologists, HCPs, Physicians, and others.

Delveinsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the University of Munich, IRCCS Policlinico San Matteo Hospital Foundation, Division of Pulmonary & Critical Care Medicine Spectrum Health–Michigan State University, the University of Pavia, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Autoimmune pulmonary alveolar proteinosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Autoimmune pulmonary alveolar proteinosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Autoimmune Pulmonary Alveolar Proteinosis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise cases of Autoimmune pulmonary alveolar proteinosis

Autoimmune Pulmonary Alveolar Proteinosis Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Autoimmune pulmonary alveolar proteinosis Epidemiology Segmentation

Autoimmune Pulmonary Alveolar Proteinosis Report Assessment

• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Autoimmune pulmonary alveolar proteinosis? What will be the growth opportunities across the 7MM concerning the patient population with Autoimmune pulmonary alveolar proteinosis?
• What is the historical and forecasted Autoimmune pulmonary alveolar proteinosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why are the diagnosed prevalence rates in European countries lower than in Japan? Why are Autoimmune pulmonary alveolar proteinosis patients not diagnosed as efficiently as in Japan?
• Which gender has a higher prevalence of Autoimmune pulmonary alveolar proteinosis?
• Which age group of Autoimmune pulmonary alveolar proteinosis has a high patient share?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the age-specific Autoimmune pulmonary alveolar proteinosis prevalence cases in varying geographies over the coming years.
• A detailed overview of stage-specific and gender-specific cases of Autoimmune pulmonary alveolar proteinosis is an inclusion.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.